Patents Examined by Deepak R. Rao
  • Patent number: 11518772
    Abstract: The present disclosure provides certain fused tricyclic ring derivatives that are Src Homology-2 phosphatase (SHP2) inhibitors and are therefore useful for the treatment of diseases treatable by inhibition of SHP2. Also provided are pharmaceutical compositions containing such compounds and processes for preparing such compounds.
    Type: Grant
    Filed: September 18, 2020
    Date of Patent: December 6, 2022
    Inventors: Jiping Fu, Yan Lou, Yigang He
  • Patent number: 11512080
    Abstract: The present invention provides compounds, compositions thereof, and methods of using the same for the inhibition of CRBN, and the treatment of CRBN-mediated disorders.
    Type: Grant
    Filed: January 14, 2019
    Date of Patent: November 29, 2022
    Inventors: Nello Mainolfi, Nan Ji, Arthur F. Kluge
  • Patent number: 11512094
    Abstract: Described herein are compounds of the formula (I), as well as pharmaceutical compositions comprising such compounds, and methods for using such compounds/pharmaceutical compositions for treating neurodegenerative diseases including Alzheimer's disease, Parkinson's disease, Huntington's disease, and multiple sclerosis (MS).
    Type: Grant
    Filed: January 11, 2019
    Date of Patent: November 29, 2022
    Assignee: University of Massachusetts
    Inventors: Jeanne A. Hardy, Penchala Narasimharao Meka
  • Patent number: 11505536
    Abstract: Disclosed are compounds, compositions and methods for treating diseases, disorders, or medical conditions that are affected by the modulation of DHODH. Such compounds are represented by Formula (I) as follows: wherein R1, R2, R3, R4, X, and Y are defined herein.
    Type: Grant
    Filed: April 16, 2020
    Date of Patent: November 22, 2022
    Inventors: Scott Kuduk, Zhuming Zhang, Lindsey DeRatt, Aihua Wang
  • Patent number: 11504375
    Abstract: Disclosed are compounds inhibiting ErbBs (e.g., EGFR or Her 2), especially mutant forms of ErbBs, and BTK, pharmaceutically acceptable salts, hydrates, solvates or stereoisomers thereof and pharmaceutical compositions comprising the compounds. The compound and the pharmaceutical composition can effectively treat ErbBs (especially mutant forms of ErbBs) or BTK associated diseases, including cancer.
    Type: Grant
    Filed: April 7, 2021
    Date of Patent: November 22, 2022
    Inventors: Zhengtao Li, Hao Zou, Wei Zhu, Changmao Shen, Rumin Wang, Wengeng Liu, Xiang Chen, Honchung Tsui, Zhenfan Yang, Xiaolin Zhang
  • Patent number: 11505541
    Abstract: PKC inhibitors are disclosed. The PKC inhibitors are useful for treating PKC associated diseases, including certain cancers. The PKC inhibitors have improved efficacy at lower dosage amounts to achieve tumor regression, improved potency, PK profile, absorption, gastrointestinal tolerance and kinase selectivity.
    Type: Grant
    Filed: March 12, 2021
    Date of Patent: November 22, 2022
    Assignee: Novartis AG
    Inventors: Michael Joseph Luzzio, Julien Papillon, Michael Scott Visser
  • Patent number: 11504369
    Abstract: Provided herein, in some embodiments, are cytosine analogs, compositions comprising cytosine analogs, and methods of use for inhibiting a Ten-eleven translocation (TET) enzyme.
    Type: Grant
    Filed: March 20, 2020
    Date of Patent: November 22, 2022
    Assignee: President and Trustees of Bates College
    Inventors: Andrew Kennedy, Gabriella N. L. Chua, Kelly L. Wassarman, Haoyu Sun
  • Patent number: 11504373
    Abstract: The present invention provides compounds and methods for treating, ameliorating, and/or preventing a MKP-5 modulated disease. In certain embodiments, the MKP-5 modulated disease is a fibrotic disease.
    Type: Grant
    Filed: December 18, 2018
    Date of Patent: November 22, 2022
    Inventors: Anton Bennett, Jonathan Ellman, Haya Jamali, Karen S. Anderson, Elias Lolis, Denton Hoyer
  • Patent number: 11498907
    Abstract: Disclosed herein are methods for preparing [(2S,3R)-N-[(2S)-3-(cyclopent-1-en-1-yl)-1-[(2R)-2-methyloxiran-2-yl]-1-oxopropan-2-yl]-3-hydroxy-3-(4-methoxyphenyl)-2-[(2S)-2-[2-(morpholin-4-yl)acetamido]propanamido]propanamide (compound “G”): and precursors thereof.
    Type: Grant
    Filed: September 9, 2020
    Date of Patent: November 15, 2022
    Inventors: Henry Johnson, Sean Dalziel, Dustin McMinn
  • Patent number: 11492332
    Abstract: Provided herein are isotopologues of Compound A, which are enriched with isotopes such as, for example, deuterium. Pharmaceutical compositions comprising the isotope-enriched compounds, and methods of using such compounds are also provided.
    Type: Grant
    Filed: March 9, 2021
    Date of Patent: November 8, 2022
    Assignee: Signal Pharmaceuticals, LLC
    Inventors: Hon-Wah Man, Mohit Atul Kothare
  • Patent number: 11471460
    Abstract: Disclosed is method for treating cancer in a mammal, comprising administering to a mammal in need thereof a compound of the formula: wherein R1, R2, and R3 are as defined herein, wherein the cancer is an autophagy-dependent cancer, in an amount sufficient to induce autophagy in the cell and cause the death of cancer cells. Also disclosed is a method for selectively killing cancer cells in a patient afflicted with cancer, comprising administering to the mammal, wherein the cancer cells are autophagy-dependent cancer cells, in an amount sufficient to induce autophagy in the cells and cause the death of the cancer cells.
    Type: Grant
    Filed: May 26, 2020
    Date of Patent: October 18, 2022
    Assignee: The United States of Americans represented by the Secretary, Department of Health and Human Services
    Inventors: Melvin L. DePamphilis, Gaurav Sharma, Juan Jose Marugan, Marc Ferrer, Ajit Roy
  • Patent number: 11472807
    Abstract: Compound of formula (I) and its addition salts with pharmaceutically acceptable acids, and methods in which an effective amount of the compound or any pharmaceutically acceptable salt thereof is administered (as a medicament) to an individual in need thereof.
    Type: Grant
    Filed: April 9, 2018
    Date of Patent: October 18, 2022
    Inventors: Aloïse Mabondzo, Charlotte Leuxe, Anne-Cécile Guyot, Nassima Oumata, Laurent Meijer
  • Patent number: 11464775
    Abstract: Described herein are methods of using compounds of Formula (I) to modulate PKM2 activity in a subject. These compounds are represented by Formula (I): wherein R1, R2, L1, and L2 are as defined herein.
    Type: Grant
    Filed: August 15, 2018
    Date of Patent: October 11, 2022
    Assignee: Agios Pharmaceuticals, Inc.
    Inventors: Giovanni Cianchetta, Charles Kung, Tao Liu, Anil Kumar Padyana, Zhihua Sui, Zhenwei Cai, Dawei Cui, Jingjing Ji
  • Patent number: 11466028
    Abstract: The present disclosure provides compounds represented by Formula I and the pharmaceutically acceptable salts, hydrates, and solvates thereof, wherein R1, R2a, R2b, R3a, R3b, R4, Ar, L, X, Y, and B are as defined as set forth in the specification. The present disclosure also provides compounds of Formula I for use to treat a condition or disorder responsive to degradation of BET bromodomains such as cancer.
    Type: Grant
    Filed: September 13, 2017
    Date of Patent: October 11, 2022
    Inventors: Shaomeng Wang, Yang Hu, Chong Qin, Fuming Xu, Jiantao Hu, Bing Zhou, Zhuo Chen, Ester Fernandez-Salas, Longchuan Bai, Donna McEachern
  • Patent number: 11465988
    Abstract: The present invention provides a process for the preparation of Tipiracil HCl of Formula (I) and intermediate thereof with improved yields and purities.
    Type: Grant
    Filed: December 13, 2019
    Date of Patent: October 11, 2022
    Inventors: Srinivasulu Sakkani, Uma Naresh Babu Kotra, Dharmender Ragidi, Buchappa Gongalla, Durga Prasad Konakanchi, Pulla Reddy Muddasani, Venkaiah Chowdary Nannapaneni
  • Patent number: 11459305
    Abstract: The present invention relates to processes and intermediates for preparing Gonadotropin-Releasing Hormone (GnRH) receptor antagonists of structure (VI); and stereoisomers and pharmaceutically acceptable salts thereof.
    Type: Grant
    Filed: January 10, 2020
    Date of Patent: October 4, 2022
    Assignee: Neurocrine Biosciences, Inc.
    Inventors: Donald J. Gallagher, Laszlo R. Treiber, Robert Michael Hughes, Onorato Campopiano, Peng Wang, Yuxin Zhao, Shine K. Chou, Michael Allen Ouellette, Donald Nicholas Hettinger
  • Patent number: 11453648
    Abstract: Provided is a method for producing an orotic acid derivative, the method comprising a condensation step of performing, under a basic condition, a condensation reaction between an orotic acid halide represented by General Formula (I) and a compound represented by General Formula (II) to generate an orotic acid derivative represented by General Formula (III); and a neutralization crystallization step of precipitating crystals of orotic acid by neutralization crystallization to separate a liquid containing the orotic acid derivative from the crystals of orotic acid, after the condensation step. In General Formula (I), (II), or (III), X is a halogen atom, and A is a group represented by General Formula (A-1) or (A-2). In General Formula (A-1) or (A-2), R1 is a hydrogen atom or an organic group, and R2 and R3 are each independently an organic group. In a case where R1 is an organic group, R1 and R2 may be bonded to each other to form a ring.
    Type: Grant
    Filed: November 7, 2019
    Date of Patent: September 27, 2022
    Assignee: SHOWA DENKO K.K.
    Inventors: Motoki Murai, Akira Shibuya
  • Patent number: 11447500
    Abstract: A thienopyridine derivative compound represented by Formula 1 or pharmaceutically acceptable salts thereof have an excellent inhibitory effect on protein kinase activity, and accordingly, pharmaceutical compositions containing the thienopyridine compound can be usefully used for the prevention or treatment of a disease associated with the activity of a protein kinase.
    Type: Grant
    Filed: March 8, 2019
    Date of Patent: September 20, 2022
    Assignee: WELLMARKER BIO CO., LTD.
    Inventors: Hyunho Lee, Chun-Ho Park, Sun Chul Hur, Jai-Hee Moon, Jae-Sik Shin, Seung-Woo Hong, Yoon-Sun Park, Joseph Kim, Sohee Lee, Hyojin Kim, Hyebin Park
  • Patent number: 11447511
    Abstract: The invention provides compounds of the formula: R1 is OR11, or NR5R5?; R2 is H or F; R5 is H, C1-C6alkyl, OH, C(?O)R6, O(C?O)R6 or O(C?O)OR6; R5? is H or C1-C6alkyl; R6 is C1-C6alkyl or C3-C7cycloalkyl; R13 is H, phenyl, pyridyl, benzyl, indolyl or naphthyl wherein the phenyl, pyridyl, benzyl, indolyl and naphthyl is optionally substituted with 1, 2 or 3 R22; and the other variables are as defined in the claims, which are of use in the treatment of cancer, and related aspects.
    Type: Grant
    Filed: November 2, 2020
    Date of Patent: September 20, 2022
    Assignee: MEDIVIR AB
    Inventors: Richard Bethell, Anders Eneroth, Bjorn Klasson, Fredrik Oberg
  • Patent number: 11446298
    Abstract: The present invention relates to pyrimidine derivatives of formula (I) wherein (R1)n, R3, R4a, R4b, R5a, R5b and Ar1 are as described in the description and their use in the treatment of cancer by modulating an immune response comprising a reactivation of the immune system in the tumor. The invention further relates to novel benzofurane and benzothiophene derivatives of formula (III) and their use as pharmaceuticals, to their preparation, to pharmaceutically acceptable salts thereof, and to their use as pharmaceuticals, to pharmaceutical compositions containing one or more compounds of formula (I), and especially to their use as modulators of the prostaglandin 2 receptors EP2 and/or EP4.
    Type: Grant
    Filed: May 17, 2018
    Date of Patent: September 20, 2022
    Inventors: Christoph Boss, Olivier Corminboeuf, Heinz Fretz, Isabelle Lyothier, Davide Pozzi, Sylvia Richard-Bildstein, Hervé Siendt, Thierry Sifferlen